# GlyTech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/glytech

- Industry: Biopolymers
- Headquarters: Kyoto, Japan
- Website: www.glytech.jp/
- Total disclosed funding: $17M
- Latest round: Series C (Jun 30, 2020)
- Investors on record: 8

## About

Founded in 2009 and based in Kyoyo, Japan, GlyTech, Inc. manufactures human type N-glycans and develops glycosylation technologies, glycopeptide synthesis, and glycoprotein synthesis. It also manages a library of human-type asparagine(Asp)-linked glycans which can be used in research and production.

## Funding rounds

- Series C, Jun 30, 2020, $1.9M — Osaka University Venture Capital
- Series B, May 28, 2018, $9.1M — SBI Investment, Osaka University Venture Capital, Nippon Shokubai Co., LTD, FUSHIMI Pharmaceutical Co., Ltd., MIAT S.p.A.
- Series A, Dec 24, 2013, $5.8M — University of Tokyo Edge Capital Partners, Mitsubishi UFJ Capital, DBJ Capital

## Investors

- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series A
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A
- DBJ Capital (https://capitalatlas.ai/funds/dbj-capital) — Series A
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series B
- Osaka University Venture Capital (https://capitalatlas.ai/funds/osaka-university-venture-capital) — Series B, Series C
- Nippon Shokubai Co., LTD — Series B
- FUSHIMI Pharmaceutical Co., Ltd. — Series B
- MIAT S.p.A. — Series B